Hyperthermia was developed by physicians and scientist. So yes, it is "purely scientific". It is, unfortunately,a slow, labor
intensive modality, and it is technically challenging, thus not very lucrative, commercially. BUT, it produces great positive
results, with absolutely no long term side effects (the only "risk" is a rare occurrence, a small superficial skin "burn" can
develope, if a patient does not report feeling the heat to an uncomfortable level.This disappears within few days..). Dr.
Raymond Royal Rife, who developed the first radiofrequency therapy device, achieved 100% success, with cancer
patients.about 80% of patients needed 3 months to achieve complete response, and the rest -one more month.He did so with
NO Chemotherapy or ionizing radiation "combination". When combining modalities, one can not properly measure the true
effect of long- term side effects of the damaging modalities. This can be done ONLY with isolating modalities, or testing the
combination versus the single modality. Since there is no financial support for such studies, we can not tell it's true potential
as a single modality practice, other than the existence of clinical studies conducted by Dr. Rife, and since, by small clinics,
the world over.There is no corporate involvement with Hyperthermia, as it is done with Pharmaceuticals.
In Europe, where it is used the longest, it is mostly used by the very rich, who know about this option. Many high profile
people have been saved by it, most of whom keep it "a private experience", unfortunately.
President Reagan and many other celebrities such as Liz Taylor, Suzanne Somers, Anthony Quinn, and including European royalty
chose Hyperthermia, and Germany’s kinder, gentler treatments.
We are posting a random compilation of studies, few of very many, done with Hyperthermia devices. Please read through it. We
use a combination of ALL radiofrequency devices, in order to prevent cancer and viruses from "adjusting" (developing biological
resistance) to the effect of a single method. In that, our facility is superior to all others.
Application of short-wave therapy in complex treatment for endometrial cancer.
Zaporozhan VN1, Khait OV, Bespoyasnaya VV.
The dynamics of the cellular immunity indices have been studied in 81 patients with endometrial cancer, during the period of
combined surgery and post-operative gamma-therapy and also during short-wave therapy. The results obtained
testify to the immunostimulating and immunomodulating effect of electromagnetic
irradiation of short-wave frequency, thus providing rehabilitation of the immune system in endometrial cancer
patients and serving as the basis for short-wave therapy, including it in the complex of therapies given to this group of
The differences in the relative dielectric permittivity and magnetic permeability, the electric conductivity and the different
ion distribution between normal and malignant tissue may explain different physical and physiological behaviour of the cells in
an electric or magnetic field. It is possible that especially electromagnetic fields in the range between 1 and 30 MHz exhibit
non-thermal antineoplastic effects on cancer cells by direct electromagnetic coupling,
f.e. with the cell membrane, receptors or ion channels. Tumour growth inhibition has been shown also for interactions with
alternating magnetic fields.71
The application of low power electric fields (<5W) has also found to be effective against cells and tumors without increasing
the temperature.72-75 Yet few studies discuss the biological mechanisms involved in the mechanisms involved with the
interactions between EMF and tissue. In his book, Exploring Biological Closed Electric Circuits (BCEC) Nordenström from the
Karolinska Institute in Stockholm79 describes different circulatory system pathways for which any serious disruption in the
flow of energy and material can produce error, malfunctions, disruptions and disease. O'Clock from Minnesota State University
could demonstrate a proliferation suppression of malignant cells (retinoblastoma cells) by direct electrical current within a 10
to 15 µA range.80
Non-equilibrium thermal effects might be-at least partially-responsible for antineoplastic effects in tumor tissue.
Capacitively-coupled energy transfer in the frequency range between 8 and 27 MHz may not penetrate the cell membrane and
will be absorbed primarily in the extracellular space. A constant energy delivery may maintain over time a temperature
gradient between the extra- and intracellular space, causing ionic currents through the membrane which depolarizes and
therefore destabilizes the membrane.76,77 An increased transmembraneous water influx by the thermal flux can increase the
intracellular pressure, which is about 30% above the normal.76 Since malignant cells typically have relatively more rigid
membranes than normal cells due to increased phospholipid concentrations,78 an increase in pressure will selectively destroy
more malignant cells.
These effects might be the reasons why RF capacitively coupled hyperthermia may be used for the treatment of areas which
have been contra indicated for other methods of hyperthermia, such as of the liver, lung, pancreas and brain.
Locoregional hyperthermia may contribute to therapeutic improvements in the treatment of cancer patients. Randomised
controlled phase III trials have shown that these methods increase at least at several indications the response
rate, disease free and overall survival of patients with cancer without increasing the toxicity of other
combinational treatments. Nevertheless, the different methods are associated with systemic and local side-effects. For
three types of tumors, the locally advanced cervical cancer, advanced head and neck tumors and glioblastoma, a survival
benefit has been shown in randomized controlled trials. In other tumors, such as local recurrent breast cancer and recurrent
melanoma an increase in local response but no positive effect on recurrence-free or overall survival has been demonstrated.
The recurrence rate of carcinoma of the bladder can be reduced markedly by hyperthermic perfusion. Patients with
peritoneal metastases from ovarian cancer respond much better to hyperthermic perfusion chemotherapy compared to
systematic chemotherapy, especially after first line therapy.
The superficial, interstitial and perfusional hyperthermic methods provide at the time the most effective hyperthermic
methods with significant improvements in clinical outcome in oncology, as quality of life and overall survival.
Further technical improvements are desired to optimize the therapeutic outcome. The optimal technique, i.e., applied
frequency, maximal temperature, time of exposure, time interval with other antineoplastic modalities, has still to be defined.
Non-invasive techniques for the measurement of the intratumoral temperature distribution may overcome the present burdened
and risky invasive measurements.
Non-thermal effects may also play a role by direct interactions of electromagnetic and ultrasonic waves in cancer
tissue, on subcellular and molecular levels. There are some interesting hints, showing that deep hyperthermia with
radiofrequencies may have some different effects and may exhibit antineoplastic activity without
radio- or chemotherapy. Marked improvements in quality of life, pain relief and prolongation of survival could be
observed in first observational studies. These encouraging results deserve to be confirmed in randomized clinical trials.
But, with respect to evidence-based gradings of clinical trials it should be mentioned that K. Benson et al,50 and J.
Concato et al,51 could show in meta-analysis from 235 clinical studies that well-designed observational
studies do not systematically overestimate the magnitude of the effects of treatment as compared
with those in randomized, controlled trials on the same topic.
I thank Mrs. M. Riese for the literature search and manuscript assistance.
Heilbrunn LV. The colloid chemistry of protoplasm. Am J Physiol. 1924;69:190–199.
Yatvin MB, Dennis WH. Membrane lipid composition and sensivity to killing by hyperthermia, Procaine and Radiation. In: Streffer C, van Beuningen
D, Dietzel F et al, eds. Cancer Therapy by Hyperthermia and Radiation. Baltimore/Munich: Urban & Schwarzenberg. 1978:157–159.
Streffer C. Biological basis of thermotherapy (with special reference to Oncology) In: Gautherie M, ed. Biological Basis of Oncologic
Thermotherapy. Berlin: Springer Verlag. 1990:1–72.
Bowler K, Duncan CJ, Gladwell RT. et al. Cellular heat injury. Comp Biochem Physiol. 1973;45A:441–450.
Belehradek J. Physiological aspects of heat and cold. Am Rev Physiol. 1957;19:59–82. [PubMed]
Wallach DFH. Action of Hyperthermia and lonizing radiation on plasma membranes. In: Streffer C, van Beuningen D, Dietzel F et al, eds. Cancer
Therapy by Hyperthermia and Radiation. Baltimore/ Munich: Urban & Schwarzenberg. 1978:19–28.
Nishida T, Akagi K, Tanaka Y. Correlation between cell killing effect and cellmembrane potential after heat treatment: analysis using fluorescent
dye and flow cytometry. Int J Hyperthermia. 1997;13:227–234. [PubMed]
Weiss TF. Cellular Biophysics, Vol. 2. Electrical Properties. Cambridge: MIT Press. 1996
Mikkelsen RB, Verma SP, Wallach DFH. Hyperthermia and the membrane potential of erythrocyte membranes as studied by Raman Spectroscopy.
In: Streffer C, van Beuningen D, Dietzel F et al, eds. Cancer Therapy by Hyperthermia and Radiation. Baltimore/Munich: Urban &
Hahn GM. The heat-shock response: Effects before, during and after Gene activation. In: Gautherie M, ed. Biological Basis of Oncologic
Thermotherapy. Berlin: Springer Verlag. 1990:135–159.
Hodgkin AL, Katz B. The effect of temperature on the electrical activity of the giant axon of squid. J Physiol. 1949;108:37–77. [PMC free
Keszler G, Csapo Z, Spasokoutskaja T. et al. Hyperthermy increase the phosporylation of deoxycytidine in the membrane phospholipid precursors
and decrease its incorporation into DNA. Adv Exper Med Biol. 2000;486:33–337. [PubMed]
Dikomey E, Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol.
Yutaka Okumura, Makoto Ihara. et al. Heat Inactivation of DANN-Dependent Protein Kinase: Possible Mechanism of Hyperthermic
Radio-sensitization. In: Kosaka M, Sugahara T, Schmidt KL, et al, eds. Thermotherapy for Neoplasia, Inflammation, and Pain. Tokyo: Springer
Weiss TF. Cellular Biophysics, Vol. 1. Transport. Cambridge: MIT Press. 1996
Dewhirst MW, Ozimek EJ, Gross J. et al. Will hyperthermia conquer the elusive hypoxic cell? Radiology. 1980;137:811–817. [PubMed]
Vaupel PW, Kelleher DK. Metabolic status and reaction to heat of Normal and tumor tisuue. In: Seegenschmiedt MH, Fesseden P, Vernon CC, eds.
Thermoradiotherapy and Thermochemotherapy, Vol. 1. Biology, physiology and physics. Berlin/Heidelberg: Springer Verlag. 1996:157–176.
Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance, and their relevance for clinical hyperthermia. Int J Hyperthermia.
Stein U, Rau B, Wust P. et al. Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance (mdr1) expression.
Int J Cancer. 1999;80:5–12. [PubMed]
Raymond U, Hiraoka M, Takahashi M. et al. Thermoradiotherapy of refractory malignant tumors: and experience with microwave and RF capacitive
hyperthermia. Medical Instrumentation. 1984;18:181–186. [PubMed]
Fuwa N, Morita K, Kimura C. et al. Combined treatment of radio-therapy and local hyperthermia using 8MHz RF-wave for advanced carcinoma of
the breast. In: Onoyama Y, ed. Hyperthermic Oncology 86 in Japan. Proceedings of the 3rd annual meeting of the Japanese Societey of
Hyperthermic Oncology. 1986:337–338.
Goldobenko GV, Durnov LA, Knysh VI. et al. Experience of the use of thermoradiotherapy of malignant tumors. Med Radiol (Russian)
Tsyb AF, Berdov BA. The use of local hyperthermia for therapy of cancer patients. Med Radiol (Russian) 1987;32:25–29. [PubMed]
Savchenco NE, Zhakov IG, Fradkin SZ. et al. The use of hyperthermia in oncology. Med Radiol (Russian) 1987;32:19–24. [PubMed]
Hamazoe R, Maeta M, Murakami A. et al. Heating efficiency of radiofrequency capacitive hyperthermia for treatment of deep-seated tumors in
the peritoneal cavity. J Surg Oncol. 1991;48:176–179. [PubMed]
Hiraoka M, Jo S, Dodo Y. et al. Clinical results of radiofrequency hayperthermia combined with radiation in the treatment of radioresistant
cancers. Cancer. 1984;54:2898–2904. [PubMed]
Kondo M, Oyamada H, Yoshikawa T. Therapeutic effects of chemoembolization using degradable starch microspheres and regional hyperthermia on
unresectable hepatocellular carcinoma. In: Matsuda T, ed. Cancer treatment by hyperthermia and drugs. London/Washington DC: Taylor & Francis.
Sugimachi K, Kuwano H, Ide H. et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective
randomized trial. Int J Hyperthermia. 1994;4:485–493. [PubMed]
Sugimachi K, Kitamura K, Baba K. Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus: a
prospective randomized trial. Int J Hyperthermia. 1992;8:289–295. [PubMed]
Sugimachi K, Kitamura K, Baba K. et al. Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the
oesophagus-A prospective randomized trial. Int J Hyperthermia. 1992;8:289–295. [PubMed]
Muratkhozhaev NK, Svetitsky PV, Kochegarov AA. et al. Hyperthermia in therapy of cancer patients. Med Radiol (Russian) 1987;32:30–36.
Wang J, Li D, Chen N. Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer.[Chinese]
Zhonhua Zhong Liu Za Zhi. 1996;18(1):51–54. [PubMed]
Shchepotin IB, Evans SR, Chorny V. et al. Intensive pre-operative radiotherapy with local hyperthermia for the treatment of gastric carcinoma.
Surg Oncol. 1994;1:37–44. [PubMed]
Kakehi M, Ueda K, Mukojima T. et al. Multi-institutional clinical studies on hyperthermia combined with radiotherapy of chemotherapy in advanced
cancer of deep-seated organs. Int J Hyperthermia. 1990;6:619–640. [PubMed]
Nagata Y, Hiraola M, Nishimura Y. et al. Radiofrequency hyperthermia for advanced gastric cancer. In: Gerner EW, ed. Hyperthermic Oncology.
Tucson: Arizona Board of Regents. 1992:407–412.
Hager ED, Krautgartner I, Popa C. et al. Deep Hyperthermia with short waves of patients with advanced stage lung cancer. Hyperthermia in clinical
practice. XXII Meeting of the International Clinical Hyperthermia Society. 1999
Hager ED, Dziambor H, Höhmann D. et al. Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer.
Anticancer Research. 1999;19:3403–3408. [PubMed]
Hager ED, Dziambor H, App EM. et al. The treatment of patients woth high-grade malignant gliomas with RF-hyperthermia. Proc ASCO.
Datta NR, Bose Ak, Kapoor HK. et al. Head and nech cancers: results of thermoradiotherapy versus radiotherapy. Int J Hyperthermia.
Overgaard J, Gonzalez D. et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma.
Lancet. 1995;345:540–43. [PubMed]
Perez CA, Pajak T, Emami B. et al. Randomized phase III study comparing irradiation and hyperthermia with irradiation alin in superficial
measurable tumors: final report by the Radiation Therapy Oncology Group. Am J Clin Oncol. 1991;14:133–41. [PubMed]
Valdagni R, Amichetti M. Report of a long-term follow-up in a randomized trial comparing radiation therapy and radiation plus hyperthermia to
metastatic lymph nodes in stage IV head and neck cancer patients. Int J Radiat Oncol. 1993;28:163–69. [PubMed]
Vernon C, Hand JW, Field SB. et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results
from five randomized collected trials. Int J Radiat Oncol Biol Phys. 1996;35:731–44. [PubMed]
Emami B, Myerson RJ, Cardenes H. et al. Combined hyperthermia and irradiation in the treatment of superficial tumors: results of a prospective
randomized trial of hyperthermia fractionation (1/wk vs 2/wk) Int Radiat Oncol Biol Phys. 1992;24:1451–52. [PubMed]
Emami B, Scott C, Perez CA. et al. Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the
treatment of recurrent or persistant human tumors. A prospectively controlled randomized study by the Radiation Therapy Group. Int J Oncol Biol
Phys. 1996;34:1097–104. [PubMed]
Sneed PK, Stauffer PR, Mc Dermott MW. et al. Survival benefit of hyperthermia in a prospective randomized trial of brachy-therapy boost +/-
haperthermia for glibostoma multiforme. Int J Radiat Oncol Biol Phys. 1998;40:287–95. [PubMed]
Kitamura K, Kuwano H, Watanabe M. et al. Prospective randomized study of hyperthermia combined with chemotherapy for esophageal carcinoma.
J Surg Oncol. 1995;60:55–58. [PubMed]
Berdov BA, Menteshashvili GZ. Thermoradiotherapy of patients with locally advanced carcinoma of the rectum. Int J Hyperthermia.
Hiraoka M, Mitsumori M, Nagata Y. Current status of clinical hyperthermic oncology in Japan.
Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–86. [PubMed]
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med.
2000;342:1887–92. [PMC free article] [PubMed]
Ohno S, Tomoda M, Tomisaki S. et al. Improved surgical results after combining preoperative hyperthermia with chemotherapy and
radiotherapy for patients with carcinoma of the rectum. Dis Colon Rectum. 1997;40(4):401–406. [PubMed]
Colombo R, Pozzo LF, Lev A. et al. Neoadjuvant combined microwave induced local hyperthermia and tropical chemotherapy versus
chemotherapy alone for superficial bladder cancer. J of Urol. 1996;155:1227–1232. [PubMed]
Colombo R, Pozzo LF, Lev A. et al. Adjuvant microwave hyperthermia and Mitomycin C versus Mitomycin C alone for superficial bladder
cancer. Europ Urol. 1999;35(suppl 2)
Hager ED, Strama H, Hohmann D. et al. Prevention of cystectomy of recurrent bladder carcinoma by intravesical hyperthermic perfusion
chemotherapy (IVHP) Antic Res. 1998;18:4807–5006.
Van Rhoon G, van der Zee J, Broekmeyer-Reurik MP. et al. Radiofrequency capacitive heating of deep-seated tumors using pre-cooling of
the subcutaneous tissues: results on thermometry in Dutch patients. Int J Hyperthermia. 1992;8:843–854. [PubMed]
Datta NR, Bose AK, Kapoor HK. Thermoradiotherapy in the management of carcinoma cervix (IIIB): a controlled clinical study. Indian Med
Hornbach NB, Shupe RE, Shidnia H. et al. Advanced stage IIIB cancer of the cervix treatment by hyperthermia and radiation. Gynecol
Oncol. 1986;23:160–167. [PubMed]
Harima Y, Nagata K, Harima K. et al. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical
carcinoma. Int J Hyperthermia. 2001;17(2):97–105. [PubMed]
Harima Y, Nagata K, Harima K. et al. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIb cervical
carcinoma. Int J Hyperthermia. 2001;17:97–105. [PubMed]
Nishimura Y, Hiraoka M, Akuta K. et al. Hyperthermia combined with radiation therapy for primary unresectable and recurrent colorectal
cancer. Int J Radiat Oncol Biol Phys. 1992;23:759–768. [PubMed]
Masunaga S, Hiraoka M, Akuta K. et al. The phase I/II trial of preoperative thermoradiotherapy in the treatment of urinary bladder
cancer. Int J Hyperthermia. 1994;10:31–40. [PubMed]
Rietbroek RC, Schiltuis MS, Bakker PM. et al. Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously
irradiated recurrent carcinoma of the uterine cervix. Cancer. 1997;79:935–942. [PubMed]
Harima Y, Nagata K, Harima K. et al. Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermotherapy in
stage IIIB cervical carcinoma. Cancer. 2000;88:132–138. [PubMed]
Masunaga S, Hiraooka M, Takahashi M. et al. Clinical results of thermradiotherapy for locally advanced and/or resurrent breast
cancer—comparison of results with radiotherapy alone. Int J Hyperthermia. 1990;6:487–497. [PubMed]
Nagata Y, Hiraoka M, Nishimura Y. et al. Clinical results of radiofrequency hyperthermia for malignant liver tumors. Int J Radiat Oncol
Biol. Phys;1197 38(2):359–365. [PubMed]
Hiraoka M, Masunaga S, Nishimura Y. et al. Regional hyperthermia combined with radiotherapy in the treatment of lung cancer. Int J
Radiat Oncol Biol Phys. 1992;22:1009–1014. [PubMed]
Hager ED, Süße B, Popa C. et al. Complex therapy of the not in sano respectable carcinoma of the pancreas—a pilot study. J Cancer Res
Clin Oncol. 1994;120(Suppl):R47P10415.
Hager ED, Dziambor H, Hoehmann D. Survival and quality of life patients with advanced pancreatic cancer. Proc ASCO.
Hiraoka M, Nishimura Y, Masunaga S. et al. Clinical results of thermoradiotherapy of soft tissue tumors. Int J Hyperthermia.
O'Clock GD. Effects of magnetic fields on health and disease. Dtsch Zschr Onkol. 2003;35:15–23.
Watson BW. Reappraisal: The treatment of tumors with direct electric current. Med Sci Rec. 1991;19:103–105.
Samuelsson L, Jonsson L, Stahl E. Percutaneous treatment of pulmonary tumors by electrolysis. Radiologie. 1983;23:284–287. [PubMed]
Miklavcic D, Sersa G, Kryzanowski M. Tumor treatment by direct electric current, tumor temperature and pH, electrode materials and
configuration. Bioelectr Bioeng. 1993;30:209–211.
Katzberg AA. The induction of cellular orientation by low-level electrical currents. Ann New York acad Sci. 1974;238:445–450. [PubMed]
Szasz A, Vincze GY, Szasz O. et al. An energy analysis of extracellular hyperthermia, accepted for publication in magneto- and
electro-biology 2003 . in print.
Kotnik T, Miklavcic D. Theoretical evaluation of the distributed power dissipation in biological cells exposed to electric field.
Bioelectromagnetics. 2000;21:385–394. [PubMed]
Galeotti T, Borrello S, Minotti L. Membrane alterations in cancer cells: the role of oxy radicals. An New York Acad Sci Vol 488.
Membrane Pathology, Bianchi G, Carafoli E, Scarpa A, eds. 1986:468–480. [PubMed]
Nordenström BEW. Biological Closed Electric Circuits: Clinical, Experimental and theoretical evidence for an additional circulatory system.
Nordic Medical Publications. Stockholm. 1983
O'Clock GD, Leonhard T. In Vitro Response of retino-blastoma, lymphoma and non-malignant cells to direct current: therapeutic
implications. Dtsch Zschr Onkol. 2001;33:85–90.
Hashimoto D, Takami M, Idezuki Y. In-depth radiation therapy by YAG laser for malignant tumors in the liver under ultrasonic imaging.
Vogl J, Mack MG, Straub R. et al. Percutaneous MRI-guided laser-induced thermotherapy fpr hepatic metastases for colorectal cancer.
Lancet. 1997;350:29. [PubMed]
Vogl J, Mack MG, Roggan A. Magnetresonanztomographisch gesteuerte laserinduzierte Thermotherapie von Lebermetastasen. Dtsch
Becker D, Hänsler JM, Strobel D. et al. Percutaneous ethanol injection and radio-frequency ablation for the treatment of nonresectable
colorectal liver metastases-techniques and results. Langenbeck's Arch Surg. 1999;384:339–343. [PubMed]
Hänsler J, Becker D, Müller W. et al. Ultraschallgesteuerte Interstitielle Hochfrequenz-Thermotherapie (HFTT)-In-vitro-Untersuchung an
der Rinderleber. Ultraschall in Med. 1998;19:59–63. [PubMed]
Kettenbach J, Köstler W, Rücklinger E. et al. Percutaneous salin-enhanced radiofrequency ablation of unresectable hepatic tumors: Initial
experience in 26 patients. AJR. 2003;180:1537. [PubMed]
Pearson AS, Izzo F, Fleming RY. et al. Intraoperative radiofrequency ablation or cryablation for hepatic malignancies. Am J Surg.
Wood TF, Rose DM, Chung M. et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and
complications. Ann Surg Oncol. 2000;7(8):593–600. [PubMed]
Jordan A, Scholz R, Maier-Hauff K. et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors
with magnetic fluid hyperthermia. J Magnetism Magn Mat. 2001;225:118–126.
Kakehi M, Ueda K, Mukomojima M. et al. Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in
advanced cancer of deep-seated organs. Int J Hyperthermia. 1996;6(4):719–740. [PubMed]
Please read these research papers- on this link- it has many references, in the notes. Thanks.
• In a clinical study conducted in Italy involving 41 patients (44 nodes) with inoperable Stage IV head and neck
cancer, patients receiving hyperthermia and radiation therapy had an 83% complete response rate compared to 41%
for patients who received radiation therapy alone, and the 3-year local relapse-free survival rate was 24% for
patients receiving only radiation and 68% for those who received both radiation and hyperthermia therapy. (See
International Journal of Radiation Oncology, Biology, Physics Vol. 28, pp. 163-169.)
• In an international clinical study conducted in Denmark, the Netherlands and Norway involving 128 patients with
recurrent or metastatic malignant melanoma, patients who received hyperthermia therapy along with radiation had a
complete response rate for recurrent malignant melanoma lesions of 62% compared to 35% for those who received
radiation treatments alone, and the local relapse-free survival rate at 5 years was 46% for those who received
both hyperthermia and radiation and 28% for those who received radiation alone. (See International Journal of
Hyperthermia, Vol., 12, No. 1, 3-20.)
Hyperthermia is a Health Canada Approved, Non-Invasive
Integrated Therapy In the Fight Against Cancer